{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T20:30:17Z","timestamp":1786393817135,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,10]]},"DOI":"10.7759\/cureus.114296","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:44:33Z","timestamp":1786391073000},"source":"Crossref","is-referenced-by-count":0,"title":["Late-Diagnosed Cystic Fibrosis in an Octogenarian With an Atypical Phenotype of Pancreatic Sufficiency and Preserved Pulmonary Function"],"prefix":"10.7759","author":[{"given":"Brenda","family":"Hranec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Layish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan JR","year":"1989","unstructured":"Riordan JR, Rommens JM, Kerem B, et al.. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989, 245:1066-73. 10.1126\/science.2475911","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181","author":"Farrell PM","year":"2017","unstructured":"Farrell PM, White TB, Ren CL, et al.. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017, 181:S4-S15. 10.1016\/j.jpeds.2016.09.064","journal-title":"J Pediatr"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study","volume":"56","author":"Andersen DH","year":"1938","unstructured":"Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child. 1938, 56:344-99.","journal-title":"Am J Dis Child"},{"key":"ref4","unstructured":"Cystic Fibrosis Foundation. 2025 Cystic Fibrosis Foundation patient registry highlights. (2026). Accessed: 8\/6\/2026: https:\/\/www.cff.org\/medical-professionals\/2025-patient-registry-highlights."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis","volume":"22","author":"Castellani C","year":"2023","unstructured":"Castellani C, Simmonds NJ, Barben J, et al.. Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis. J Cyst Fibros. 2023, 22:963-8. 10.1016\/j.jcf.2023.09.008","journal-title":"J Cyst Fibros"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani C","year":"2018","unstructured":"Castellani C, Duff AJ, Bell SC, et al.. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018, 17:153-78. 10.1016\/j.jcf.2018.02.006","journal-title":"J Cyst Fibros"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton PG","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, et al.. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019, 381:1809-19. 10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman HG","year":"2019","unstructured":"Heijerman HG, McKone EF, Downey DG, et al.. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019, 394:1940-8. 10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating C","year":"2025","unstructured":"Keating C, Yonker LM, Vermeulen F, et al.. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025, 13:256-71. 10.1016\/S2213-2600(24)00411-9","journal-title":"Lancet Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.09540522","article-title":"Cystic fibrosis pulmonary guidelines: airway clearance therapies","volume":"54","author":"Flume PA","year":"2009","unstructured":"Flume PA, Robinson KA, O'Sullivan BP, et al.. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009, 54:522-37. 10.4187\/respcare.09540522","journal-title":"Respir Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.23.3.545","article-title":"A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis","volume":"23","author":"Gibson LE","year":"1959","unstructured":"Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959, 23:545-9. 10.1542\/peds.23.3.545","journal-title":"Pediatrics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-228821","article-title":"Atypical presentation of cystic fibrosis at 70 years of age","volume":"12","author":"Saleem MA","year":"2019","unstructured":"Saleem MA, Phillips A, Ganaie MB. Atypical presentation of cystic fibrosis at 70 years of age. BMJ Case Rep. 2019, 12:10.1136\/bcr-2018-228821","journal-title":"BMJ Case Rep"},{"key":"ref13","unstructured":"US Food and Drug Administration. TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor) label. (2024). Accessed: 8\/6\/2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212273s013lbl.pdf."},{"key":"ref14","unstructured":"US Food and Drug Administration. ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor) label. (2024). Accessed: 8\/6\/2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218730s000lbl.pdf."},{"key":"ref15","article-title":"Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek)","year":"2025","unstructured":"Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek). Canadian Agency for Drugs and Technologies in Health, Ottawa, ON; 2025."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2025.12.021","article-title":"Financial and healthcare tradeoffs associated with cystic fibrosis care in the United States: a cross-sectional study","volume":"25","author":"Van Citters AD","year":"2026","unstructured":"Van Citters AD, Carey K, Ren CL, et al.. Financial and healthcare tradeoffs associated with cystic fibrosis care in the United States: a cross-sectional study. J Cyst Fibros. 2026, 25:296-304. 10.1016\/j.jcf.2025.12.021","journal-title":"J Cyst Fibros"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/515622-late-diagnosed-cystic-fibrosis-in-an-octogenarian-with-an-atypical-phenotype-of-pancreatic-sufficiency-and-preserved-pulmonary-function","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:44:35Z","timestamp":1786391075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/515622-late-diagnosed-cystic-fibrosis-in-an-octogenarian-with-an-atypical-phenotype-of-pancreatic-sufficiency-and-preserved-pulmonary-function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.114296","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}